Eli Lilly & Co.’s stock rose 1.6% Wednesday, after the drug company announced plans to expand its U.S. manufacturing sites by adding four more locations this year, along with 13,000 high-wage jobs.

The Annual and Half-year Reports are also available in our app - with the advantage that they can also be read offline and can be navigated in a particularly user-friendly manner. Since 1998 the ...

That negative investor reaction was directed at companies involved in the white-hot weight loss drug segment of the market (Eli Lilly is the pharmaceutical giant behind a popular one, Zepbound).

March 10 (Reuters) - Eli Lilly (LLY.N), opens new tab plans to launch its blockbuster diabetes and weight-loss drug in major emerging markets like India, Brazil and Mexico in the second half of ...

Earlier this week, Eli Lilly partnered up with telehealth providers LifeMD and Teladoc Health to offer its lower cost, single-vial Zepbound (tirzepatide) to patients in the virtual care companies ...

A federal court in Texas has rejected a request by producers of compounded drugs to extend their ability to manufacture knockoff versions of Eli Lilly's tirzepatide while a lawsuit plays out.

(Photo courtesy of Adam Seif) Michael Headrick of Indianapolis wanted to start on a new GLP-1 medication for weight loss, so he mentioned Eli Lilly and Co.’s Zepbound to his doctor, who agreed ...